VTVT News and Press, vTv Therapeutics Inc.

2024-07-26 16:29:26 ET More on vTv Therapeutics Financial information for vTv Therapeutics Read the full article on Seeking Alpha For further details see: FDA places clinical hold on vTv's cadisegliatin clinical program

HIGH POINT, N.C., July 26, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead program in diabetes, today announced that the United States Food and Drug Administration (FDA) has pla...

2024-06-26 16:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Cadisegliatin is a potential first-in-class oral liver selective glucokinase activator for T1D, which has been granted Breakthrough Therapy designation by the FDA for T1D Cadisegliatin has been dosed in over ...

2024-05-30 11:22:06 ET More on Eli Lilly, Novo, etc. Novo Nordisk: The Market Is Right, Don't Fight Against It Novo Nordisk: Not The Best Investment Right Now, But A Great Case Study Novo Nordisk: Considerable Growth Beyond Ozempic Lilly's Retevmo gains appro...

CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING PR Newswire WESTON, Fla. , May 28, 2024 /PRNewswire/ -- Cantex Pharmaceuticals , Inc., a clinical stage pharmaceutical company focused on developi...

2024-05-20 13:27:56 ET More on vTv Therapeutics Financial information for vTv Therapeutics Read the full article on Seeking Alpha For further details see: Cantex Pharmaceuticals receives FDA Orphan Drug Designation for its pancreatic cancer treatment

2024-05-09 17:37:56 ET More on vTv Therapeutics Financial information for vTv Therapeutics Read the full article on Seeking Alpha For further details see: vTv Therapeutics GAAP EPS of -$1.17, revenue of $1M

HIGH POINT, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today reported financial results for the first quarter e...

2024-04-16 19:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...